Cardiol Therapeutics

Cardiol Therapeutics, Inc. is a clinical-stage life sciences company focused on the research and clinical of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. The firm is conducting clinical studies to evaluate the efficacy and safety of CardiolRx in diseases affecting the heart: a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial) in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis. It is also involved in developing a novel subcutaneously administered drug formulation of cannabidiol intended for use in heart failure. The company was founded by David Elsley, Eldon Smith, and Anthony Bolton on January 19, 2017 and is headquartered in Oakville, Canada.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oakville, Ontario--(Newsfile Corp. - May 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that its Board of Directors has appointed Teri Loxam and Chris Waddick to serve as directors, effective immediately. Ms. Teri Loxam has over 25 years of experience in the...

Cardiol Therapeutics Appoints Teri Loxam and Chris Waddick to its Board of Directors

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced that the US Food and Drug Administration has authorized its Investigational New Drug Application to start its Phase II open-label pilot study. The study will evaluate the tolerance and safety of Cardiol's lead drug CardiolRx, a pharmaceutically-manufactured oral cannabidiol formulation for patients with recurrent pericarditis.

Cardiol Therapeutics receives US FDA authorization for Phase II study of CardiolRx for recurrent pericarditis

Third IND authorization for CardiolRx™ in cardiovascular diseaseStudy to run in parallel with Company's multi-national Phase II acute myocarditis trial, expected to commence imminently CardiolRx™ is now eligible for orphan drug status in two indicationsOakville, Ontario--(Newsfile Corp. - May 17, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular...

Cardiol Therapeutics Announces FDA Investigational New Drug Application (IND) Authorization for Multicenter Phase II Open-Label Pilot Study of CardiolRx(TM) for Recurrent Pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc CEO David Elsley told investors that the clinical-stage life sciences company is “well positioned” to pursue the development of new treatment options for patients living with heart disease. In a look back at its 2021 year, Elsley said the firm accomplished “several important goals” related to the development of its pharmaceutically produced cannabidiol formulations for use as an anti-fibrotic and anti-inflammatory therapy in cardiovascular disease.

Cardiol Therapeutics looks ahead to busy 2022 as it advances new treatment options for cardiovascular disease

Expanded the Phase II/III LANCER clinical trial in patients with cardiovascular disease (CVD), or significant CVD risk factors, who are hospitalized with COVID-19Received authorization from the FDA to proceed with the Company's IND to commence a Phase II multi-national clinical trial in patients with acute myocarditisMade strategic appointments to senior management team Listed on the NASDAQ stock exchangeEnded 2021 with cash and cash equivalents of $83.9MOakville, Ontario--(Newsfile Corp. - March 24, 2022) - Cardiol Therapeutics...

Cardiol Therapeutics Announces Year-End 2021 Update on Operations

Oakville, Ontario--(Newsfile Corp. - March 22, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that Cardiol's Chief Medical Officer, Dr. Andrew Hamer, will be participating in a panel discussion entitled "New World Order for Endo/CV/Renal Disease" at Cantor Fitzgerald's Virtual Rare Orphan Disease Summit on Tuesday, March...

Cardiol Therapeutics to Participate in Cantor Fitzgerald's Virtual Rare Orphan Disease Summit

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc has announced that Jennifer M. Chao has been appointed as a director of the company, effective immediately.

Cardiol Therapeutics says Jennifer M. Chao has been appointed as director of the company

Oakville, Ontario--(Newsfile Corp. - March 15, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), is pleased to announce that its Board of Directors has appointed Jennifer M. Chao to serve as a director, effective immediately. Ms. Chao has also been appointed Chair of the Corporate Governance and Compensation...

Cardiol Therapeutics Appoints Jennifer M. Chao to Its Board of Directors

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced it has received clearance from the US Food and Drug Administration and its counterparts in Brazil and Mexico to modify the inclusion criteria for its LANCER trial to potentially expedite patient enrollment. The modifications will allow the enrollment of vaccinated patients, among other things, to broaden the eligible population, according to Oakville, Ontario-based Cardiol.

Cardiol Therapeutics receives clearance to expand eligible patient group for its LANCER study

LANCER Trial expanded to include up to 20 Additional Clinical Research CentersOakville, Ontario--(Newsfile Corp. - March 1, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease ("CVD"), today announced that it has received clearance from the FDA and regulatory agencies in Brazil and Mexico to modify the inclusion criteria for the LANCER trial to allow for, amongst other things, the enrollment...

Cardiol Therapeutics Receives Clearance from the FDA and Regulatory Agencies in Brazil and Mexico for Important Protocol Amendments Designed to Expedite Patient Enrollment in the LANCER Trial

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc has appointed three new cardiovascular experts to its Scientific Advisory Board. The clinical-stage life sciences company welcomed Dr Paul Ridker, Dr Bruce McManus and Dr Joseph A Hill to the board.

Cardiol Therapeutics appoints three new members to its Scientific Advisory Board

Oakville, Ontario--(Newsfile Corp. - January 19, 2022) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Ridker, MD, MPH, Bruce McManus, PhD, MD, and Joseph A. Hill, MD, PhD, to its Scientific Advisory Board (SAB). "We are pleased to welcome distinguished thought leaders in...

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

Aurora Cannabis

AFC Gamma

Agrify

Arena Pharmaceuticals

Alpine Global Premier Properties Fund

Cambria Global Real Estate ETF

Canopy Growth

Clever Leaves Holdings Inc

Amplify Seymour Cannabis ETF

Cronos Group

Direxion Daily CSI China Internet Index Bull 2X Shares

WisdomTree Global ex-US Real Estate Fund

Invesco S&P 500 Equal Weight Real Estate ETF

First Trust FTSE EPRA/NAREIT Developed Markets Real Estate

Fidelity MSCI Real Estate ETF

First Trust S&P REIT Index Fund

Greenlane Holdings

FlexShares Global Quality Real Estate Index Fund

GrowGeneration Corp

Xtrackers International Real Estate ETF

High Tide

Hydrofarm Holdings Group

High on Growth: Cannabis REITs are far-and-away the best-performing REIT sector of the past half-decade as the budding industry thrives in the murky and often contradictory regulatory framework of legalized marijuana. Joining Innovative Industrial, Power REIT, and AFC Gamma, a pair of newcomers will soon enter the pot party - Chicago Atlantic Real Estate Finance and Freehold Properties - both operating as mortgage REITs.

Cannabis REITs: When They Go Low, We Get High

Cardiol Therapeutics is developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease. The company's lead candidate CardiolRx is an ultra-pure, high concentration cannabidiol oral formulation.

Cardiol Therapeutics: Developing Anti-Inflammatory CBD Therapies For CVD

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) Inc announced it has closed a US$50 million public offering to advance its research and clinical development programs. The clinical-stage biotechnology company is focused on the research and clinical development of innovative anti-inflammatory therapies for the treatment of cardiovascular disease.

Cardiol Therapeutics raises US$50M to advance research and clinical development initiatives

Oakville, Ontario--(Newsfile Corp. - November 5, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing anti-inflammatory therapies for the treatment of cardiovascular disease, announced today the closing of its previously announced public offering (the "Offering") of 16,350,000 units of the Company (the "Units") at a price to the public of US$3.07 per Unit for gross proceeds of US$50,194,500, before deducting the underwriting discounts and...

Cardiol Therapeutics Announces Closing of US$50 Million Public Offering

Today, CRDL stock is down despite very positive news of a Health Canada approval for a Phase 2 trial of the company's leading drug. The post CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Therapeutics appeared first on InvestorPlace.

CRDL Stock: 7 Things to Know About Healthcare Play Cardiol Therapeutics

Cardiol Therapeutics Inc announced it has received Health Canada approval to proceed with its Phase II trial of lead drug CardiolRx for acute myocarditis. The multi-center, double-blind, randomized, and placebo-controlled trial will look at the safety and tolerability of CardiolRx as well as its impact on myocardial recovery in patients with the debilitating condition.

Cardiol Therapeutics receives Health Canada approval for Phase II trial of CardiolRx

Oakville, Ontario--(Newsfile Corp. - October 25, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that it has received approval from Health Canada to proceed with the Company's Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety and tolerability of CardiolRx™ as well as its impact on myocardial...

Cardiol Therapeutics Receives Health Canada Approval for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

Cardiol Therapeutics Inc announced it is expanding its LANCER clinical trial to Brazil, Mexico, and Canada. LANCER is a Phase II/III randomized, double-blind, placebo-controlled safety and efficacy trial of the company's lead drug CardiolRx in patients with coronavirus (COVID-19) who are at risk of, or dealing with, cardiovascular disease.

Cardiol Therapeutics announces expansion of LANCER Phase II/III trial to three new countries

Cardiol Therapeutics Inc. has announced the appointment of Michael J.

Cardiol Therapeutics announces appointment of Michael J. Willner to its board of directors, effective immediately

Oakville, Ontario--(Newsfile Corp. - September 7, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce the appointment of Michael J. Willner, Esq. to its Board of Directors, effective immediately.Michael J. Willner has practiced as both an Attorney and a Certified Public Accountant. He graduated from Emory University Law School as a...

Cardiol Therapeutics Appoints Michael J. Willner to Its Board of Directors

Proprietary formulation produces ultra-pure pharmaceutical cannabidiol (CBD) without the psychotropic effects of THC for the treatment of inflammatory heart disease Received US FDA approval to commence a Phase II/III COVID-19 trial investigating the cardioprotective properties of CardiolRx Investigational New Drug (IND) application cleared by the FDA for a Phase II international trial assessing the safety and tolerability of CardiolRx, as well as its impact on myocardial recovery in patients presenting with acute myocarditis What Cardiol Therapeutics does: Cardiol Therapeutics Inc (TSE:CRDL) (OTCQX:CRTPF) is a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease. The Canadian specialty pharmaceutical company has developed a proprietary formula of ultra-pure pharmaceutical cannabidiol (CBD) that does not contain THC - less than 10 parts per million (ppm) - and consequently none of the psychotropic effects of THC.

Cardiol Therapeutics is commercializing its THC-free cannabidiol formulation to treat heart disease

Cardiol Therapeutics Inc. has announced that the US Food and Drug Administration approved its Investigational New Drug (IND) application for a Phase II trial to study the safety and tolerability of CardiolRx as well as its impact on recovery in patients with acute myocarditis.

Cardiol Therapeutics wins FDA approval for clinical trial of CardiolRx to treat patients with acute myocarditis

Oakville, Ontario--(Newsfile Corp. - August 24, 2021) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, is pleased to announce that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed with the Company's Investigational New Drug (IND) application to commence a Phase II, multi-center, double-blind, randomized, placebo-controlled trial designed to study the safety...

Cardiol Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for Phase II Clinical Trial of CardiolRx(TM) for Acute Myocarditis

News for Cardiol Therapeutics Stock (CRDL)